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Abstract
Background/Aim. Diabetes mellitus (DM) is a metabolic
disorder characterized by hyperglycemia. The aim of this
study was to explore the prognosis of patients with juvenile
DM regarding diabetic eye complications, as well as the
course of the diabetic eye disease related to the treatment
undertaken. Methods. The study series involved 33 patients
with juvenile DM during the period 1992–2007. The influ-
ence of the following factors on the course of the disease
was estimated: age, the age of the disease onset, time when
eye complications appeared, treatment modalities. Results.
Of the total of 33 diabetics 15 patients were followed for 10
or more years and 18 from 5 to 9 years. At the time of their
first visit the mean age was 23.12 ±  6.39 and the mean du-
ration of DM was 17.42 ± 7.42 years. On their first visit, 7
eyes were without any complication. Most of the patients al-
ready developed clinical signs of proliferative diabetic reti-
nopathy (41.39%), the signs of nonproliferative diabetic
retinopathy (13.13%) and macula involvement (10.10%).
Diabetic cataract was found in 8.8% as well as tractional
retinal detachment. Eleven out of 66 eyes were with vitre-
ous hemorrhage. Two patients (5.5%) suffered neovascular
glaucoma. There was 1 (2.2%) patient with developed ru-
beosis iridis and simplex glaucoma. Panretinal photocoagu-
lation was performed in 65% of patients, focal photoco-
agulation in 15%, 12% patients underwent pars plana
vitrectomy and 4% had cataract surgery with intraocular
lens implantation and peripheral retinal kryopexy. Conclu-
sion. Total vision loss due to eye complications of juvenile
DM may be prevented if timely diagnosed with regular
check ups and early treatment.
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Apstrakt
Uvod/Cilj. Dijabetes melitus (DM) je metabolički pore-
mećaj koji karakteriše hiperglikemija. Cilj studije bio je da
se ispita prognoza vida bolesnika sa insulin-zavisnim juve-
nilnim DM, kao i efekta lečenja komplikacija dijabetičke
bolesti oka. Metode. U studiju su bila uključena 33 boles-
nika sa juvenilnim DM u periodu 1992–2007. Razmatran
je uticaj sledećih faktora na tok bolesti: životno doba bole-
snika, vreme početka bolesti, vreme pojave komplikacija,
vrsta lečenja. Rezultati. Od ukupnog broja bolesnika, 15
su praćeni u periodu od 10 i više godina, a 18 od pet do
devet godina. U vreme prvog oftalmološkog pregleda, sre-
dnje životno doba obolelih bilo je 23,12 ± 6,39, a srednje
vreme trajanja bolesti je 17,42 ± 7,42 godine. Na prvom
pregledu sedam očiju bilo je bez dijabetičkih promena. Ve-
ćina drugih bolesnika imala je komplikacije u vidu prolife-
rativne dijabetičke retinopatije (41,39% očiju), neprolifera-
tivne dijabetičke retinopatije (13,13% očiju), dok je makula
bila zahvaćena kod 10,10% očiju. Dijabetička katarakta
bila je prisutna kod 8,8%, kao i trakciona ablacija retine.
Jedanaest od 66 očiju imalo je vitreusne hemoragije. Dva
bolesnika (5,5% očiju) bolovalo je od neovaskularnog gla-
ukoma. Jedan bolesnik (2,2% očiju) imao je rubeozu duži-
ce i simpleks glaukom. Urađena je panretinalna fotokoa-
gulacija 65% očiju, fokalna fotokoagulacija 15%, pars pla-
na vitrektomija 12%, dok je 4% operisano zbog katarakte
uz ugradnju intraokularnog sočiva i perifernom kriopeksi-
jom retine. Zaključak. Potpuni gubitak vida kao posledica
komplikacija juvenilne dijabetičke bolesti oka može se
prevenirati pravovremeno postavljenom dijagnozom, ure-
dnim kontrolama i adekvatnom terapijom.
Ključne reči:
dijabetes melitus, insulin-zavisni; dijabetesna retino-
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Introduction
Diabetes mellitus (DM) is a metabolic disorder charac-
terized by hyperglycemia. In the Western World, approxi-
mately 1% of the population is diabetic, and at least another
1% is with undiagnosed high levels of serum glucose. Juve-
nile onset insulin-dependent DM (IDDM) accounts for ap-
proximately 10–15% of DM, the remainder being maturity
onset or non insulin-dependent diabetics. Aside from acute
glucose serum level abnormalities, the main risks to health
are the characteristic long-term complications. These include
cardiovascular diseases, chronic renal failure, retinal and
nerve damages 
1.
Retinal damage is presented with diabetic retinopathy
(DR) which is the most frequent complication of diabetes
and a leading cause of impaired vision in the Western World.
It is well-known that the age of onset and the duration of
diabetes are the strongest risk factors for development and
progression of retinopathy 
2, 3, which can be presented in the
form of nonproliferative (NPDR), preproliferative or prolif-
erative form (PDR), depending on the presence of the new
blood vessels on the surface of retina or optic disc. For juve-
nile onset IDDM, PDR is the most frequent finding 
3.
The essence of eye complications are the mechanisms
through which microvascular occlusion transforms DR into
an ischemic retinopathy, with neovascularisation 
4, 5. The
first pathologic sign seen in the retina are retinal capillary
microaneurysms. They cause the development of excessive
vascular permeability and therefore leakage. Further, micro-
vascular occlusion occurs followed by the proliferation of
new blood vessels and accompanying
 fibrous tissue on the
surface of the retina and optic disk which contracts together
with the vitreous. Further, bleeding that occurs from new
blood vessels and contraction of the fibrous tissue compro-
mises visual acuity (VA) through hemophthalmos or trac-
tional retinal detachment. If the process spreads to the ante-
rior part of the eye, neovascular glaucoma develops with
painful eye and total vision loss. Aside from these severe
complications, VA is more often compromised through
macular edema, due to disruption and increased permeability
of perifoveolar capillary network, in a form of clinically sig-
nificant macular edema.
In attempt to avoid diabetic eye complications and total
visual loss, laser photocoagulation (LFK) of retina is indi-
cated. It may be performed in a form of focal or panretinal
LFK (PRP). The aim of these procedures is to decrease reti-
nal ischemia through direct destruction of the retinal tissue
and reduction of angiogenic factors indirectly. There are also
opinions that pigment epithelial proliferation after photoco-
agulation has some antiangiogenic effect 
6.
New vessel proliferation is a consequence of the effect
of angiogenic factors, delivered from the ischemic retinal tis-
sue. Researchers learn more about how angiogenic agents
such as vascular endothelial growth factor, as well as the iso-
enzyme protein kinase C beta conspire to disrupt endothelial
cell function, leading to increased retinal vascular perme-
ability. In that sense, modern investigations are trying to find
an answer to the question whether pharmacological treat-
ments might someday supplement LFK as a preferable early
intervention for diabetic eye disease 
7–10. But, until new
therapeutic possibilities are available, we have to perform
PRP in order to save patient’s vision, although there are
some undesirable effects of it, such as compromised VA,
visual field constriction, color vision perception distur-
bances, reduced contrast sensitivity and night vision.
Therefore, in order to gain a better understanding of this
serious disease, the authors performed a 15-year follow up
based on young patients with IDDM–related eye complica-
tions and therapy performed in order to save VA. The base
for this research is general agreement that early diagnosis
and treatment of DR can slow its progression and help to
prevent blindness 
1, 11.
Methods
A retrospective study was based on records of 33 patients
(66 eyes) diagnosed with juvenile onset DM at the Department
of Ophthalmology, University Hospital ”Zvezdara”, Belgrade,
Serbia, between 1992 and 2007. All the patients came with the
diagnosis of juvenile-onset IDDM.
All the patients were examined by the same ophthal-
mologists (authors) for at least five times and the examina-
tion included the same procedure. An incorrected best VA
and best corrected VA were taken, intraocular pressure
measurments with Goldmann applanational tonometry, ex-
amination on the slit lamp and finally, after pupil dilatation,
optic disc and retina were evaluated. Fundoscopy was per-
formed by direct and indirect ophthalmoscopy (included
biomicroscopy).
The diagnosis of DR was established based on its char-
acteristic presentation, either as a NPDR or PDR form. Fluo-
rescein angiography was obtained for the small number of
patients. It was done in cases in which clinical presentation
was not sufficient for classification of retinopathy. It was
performed also in cases with maculopathy to ease focal
photocoagulation. Slit lamp presentation of rubeosis iridis,
neovascular glaucoma or cataract formation were recorded,
too. During the treatment, ophthalmologic evaluation was
performed to determine new retinal lesions, enlargement of
pre-existing lesions, and changes in their appearance.
As a complication of DR we posed a diagnosis of ru-
beosis iridis, neovascular glaucoma, cataract, partial or total
hemophthalmos and tractional retinal detachment.
The treatment was initiated as soon as the diagnosis was
confirmed. Depending on the type of changes, we performed
focal LFK or PRP, cataract surgery with intraocular lens im-
plantation, glaucoma medications, pars plana vitrectomy or
peripheral retinal kryopexy.
All analyses were performed using an electronic data-
base organized in the SPSS (version 11.5) statistical package.
Descriptive methods were used for mean values of the onset
of DM, age of patients, gender, etc. The effects of treatment
to VA, and VA on the first and the last examination were
compared by the one-way ANOVA, with the level of signifi-
cans of 0.05. The Kaplan-Meier survival method was used to
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Results
We reviewed the charts of 33 patients with juvenile
IDDM, out of which 39.39% males and 60.60% females. The
youngest patient at the first visit was 12-year old and the
oldest one was 37, with the mean age of 23.12±6.39 years.
The minimum duration of DM was 7 years and the maximum
33 years with the mean 17.42±7.42 years. The age at which
the diagnosis of DM was first established was as little as 2
and as big as 19, with the mean age of 8.61±4.27 years.
For 15 patients we reviewed the charts for more than 10
years of a regular follow-up and for 18 patients from 5 to 9
years of a regular follow-up.
In 13 eyes the first eye complication developed 6 to 10
years from the beggining of the diesease. In 30 eyes DM
lasted betwen 11 and 20 and in 16 eyes over 21 years before
the first signs of ophthalmological complications were no-
ticed. After 20 years of duration there were no patients (eyes)
without complications. Using the Kaplan Meier test of prob-
ability, we can see that after 10 years of duration 50% of pa-
tients would have some complications, but after 20 years of
DM, almost 90% of patients would have it, and this differ-
ence is significant.
On their first visit, a diagnosis of PDR was established
in 41.39% of the patients, NPDR at 13.13%, macula was in-
volved in 10.10% of the patients. Cataract was found in 8.8%
as well as tractional retinal detachment. Seven of 66 eyes
were without any changes at the first visit. Eleven of 66
(16.66%) eyes had vitreous gel hemorrhage. Neovascular
glaucoma suffered 5.5% of the patients. There were 2.2%
with rubeosis iridis and simplex glaucoma.
Panretinal laser photocoagulation was performed in
65% of the patients, focal treatment in 15%, 12% had pars
plana vitrectomy and 4% had cataract surgery and peripheral
retinal kryopexy. We compared best corrected VA at the first
visit with best corrected VA at the last visit according to the
therapy performed, and found statistical significance (p =
0.037 and p = 0.045).
Visual acuity at the time of first visit was as follow:
none of the patients were blind, light perception had 7 eyes,
14 eyes had VA less than 0.7 and 45 eyes had VA of 0.8 or
better. At the last visit 7 of the eyes were blind, two had light
perception, 14 eyes had VA less than 0.7 and VA of 0.8 and
better had 43 eyes. The VA at the first and last visit differed
significantly (p = 0.00).
Discussion
Diabetic retinopathy is the most frequent complication
of diabetes and a leading cause of impaired vision in most
countries. Its asymptomatic nature and its etiopathogenesis,
which is still unclear due to its multifactorial complexity
makes DR-related blindness a growing social problem in
many countries 
12. This refers especially to the cases of juve-
nile-onset DM.
Physicians are aware of the fact that with the age of onset
and the duration of juvenile diabetes, the development and
progression of retinopathy rises 
1, 11, 13. Still, it remains un-
known which is the best time to start with controls of young
diabetics, having in mind that there are still some subjects who
develop mild changes in spite of a long duration of disease.
Burger et al. 
3 point out that compared with ophthal-
moscopy, as performed by an experienced ophthalmologist,
fluorescein angiography allows detection of retinal changes
about 4 years earlier.
Some authors confirm that preschool-age children at the
onset of diabetes stay free from even minimal retinal compli-
cations longer than adolescents. Furthermore, the “onset” of
retinopathy over 15 years of age in the great majority of sub-
jects suggests some influence of sexual maturation during pu-
berty 
3, 14. Based on up to date studies, yearly exams are not
necessarily required for juvenile-onset diabetics within the first
decade of life, but should be performed after 5 years of diabe-
tes in younger children and after 2 years in adolescents 
15.
On the other hand, proliferative changes may develop in
previosly “normal” fundus from one examination to another
within only two years in young diabetics 
3.
Most of our patients had complications on their first
visit. There were no patients with DM lasting less than 7
years. The mean age of duration of DM was 17.42 ± 7.42
and the mean age at their first visit was 23.12 ± 6.39 years.
In our series, the risk of severe eye complications rose
with the duration of diabetes, so that after 10 years of dura-
tion almost half of the patients had some complications,
while after 20 years, none of the patients was without com-
plication (p < 0.05).
In the series of Krolewsky et al.
16, the risk of develop-
ment of severe eye complications was almost
  nonexistent
during the first 10 years of diabetes, but rose abruptly to its
maximum level, and remained at that
 level for the next 25
years. Other authors report that the median risk age for the
development of retinopathy 17.5 years, which is consistent
with our findings 
5, 16, 17.
In our serie the most common DM-related complication
on the first visit was PDR (41.39%). Some authors mention
different percents (21.6%; 55.2%) 
13, 16–18.
To avoid blindness, nowadays methods include medical
management (control of blood sugar, blood pressure, and se-
rum lipids) and ocular management (LFK and pars plana
vitrectomy). Adjunctive pharmacologic therapies (intravit-
real triamcinolone acetonide and antivascular endothelial
growth factor agents) have shown early promise in the treat-
ment of both diabetic macular edema and PDR 
15. Mean-
while, laser treatment is still the gold standard of treatment
for focal and diffuse diabetic macular edema and PDR, al-
though its associations with some decline in visual functions
are expected 
2, 15, 19– 22. When properly treated, PRP reduces
the risk of moderate and severe visual loss by 50–90% in pa-
tients with severe NPDR and PDR, and the risk of visual loss
from macular edema by 50–70% 
22–25. Some other treatment
possibilities are recommended in cases in which PRP is not
enough, like pars plana vitrectomy, cataract surgery and pe-
ripheral retinal kryopexy 
26–29.
The goal of these treatments is to obtain good VA. Yet,
VA in our patients was worse at the end of the study. This is
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tions already developed, so the therapy had no beneficial ef-
fect. These values for VA were statisticaly significant
(p = 0.00). On the other hand, patients who came with PDR
and less macular involvement, kept their VA for a long pe-
riod of time. In the series of some authors, VA was guarded
through the study (0.5 and better) and at the end of their
treatment, although they did not find any significance in a
VA before and after the therapy 
30.
Visual stability after PRP indicated the need for this
kind of treatment in an early phase of PDR in order to pre-
serve visual function.
Conclusion
According to our results, we would like to confirm and
support the opinion that if a patient with DM refers to oph-
thalmologist on time, VA could be saved for a long period of
time. In that sence, the most important are early detection of
the disease, intensive metabolic control, patient education
about asymptomatic nature of DR and the use of screening
programs for the youngsters from the age of 10 years. In case
of present complications the treatment should be considered
as soon as possible.
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